MarketPulse
A

$ARVN

4 articles found
4 positive
0 negative
0 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Arvinas Wins Historic PROTAC Approval; Eyes Q1 2026 Results on May 12

Arvinas wins landmark FDA approval for VEPPANU, first PROTAC protein degrader for breast cancer, ahead of schedule. Reports Q1 2026 results May 12.
PFEARVNFDA approvalbiotech
BenzingaBenzinga··Vandana Singh

Pfizer, Arvinas Secure FDA Approval for Groundbreaking PROTAC Breast Cancer Drug

FDA approves VEPPANU, first PROTAC therapy for advanced breast cancer with ESR1 mutations, showing 43% reduction in disease progression risk versus existing treatment.
PFEARVNGHFDA approvalbreast cancer
GlobeNewswire Inc.GlobeNewswire Inc.··Arvinas, Inc.

Arvinas Wins FDA Nod for First PROTAC Breast Cancer Drug

Arvinas and Pfizer secure FDA approval for VEPPANU, the first PROTAC protein degrader, for ESR1-mutated breast cancer based on Phase 3 data showing 43% progression-risk reduction.
PFEARVNFDA approvalbreast cancer
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Arvinas to Showcase ARV-102 Parkinson's Data at Major Neurology Conference

Arvinas will present Phase 1 data for ARV-102, a PROTAC LRRK2 degrader, at AD/PD 2026 conference in Copenhagen, with Phase 1b trial planned for progressive supranuclear palsy.
ARVNPhase 1 clinical trialParkinson's disease